Is Egrifta (Tesamorelin) Legal in Kentucky?

What Is Tesamorelin and Why Does Legal Status Matter?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates endogenous growth hormone secretion, which in turn reduces visceral adipose tissue. The FDA approved it specifically for excess abdominal fat in adults with HIV who are on antiretroviral therapy [1].

Legal status matters because the peptide market includes many substances sold as "research chemicals" with no regulatory oversight. Tesamorelin sits in a different category: it has a named FDA approval, a defined drug master file, and a clear prescribing pathway. Patients and clinicians in Kentucky who understand that framework can access it safely and lawfully.

Why Peptide Legal Status Varies by Compound

Not every peptide follows the same rules. BPC-157 has no FDA approval and no accepted compounding pathway. Semaglutide (Ozempic/Wegovy) is an FDA-approved small molecule with an active compounding shortage exemption. Tesamorelin sits in its own position: approved for one indication, not a controlled substance, but with compounding access tightly constrained by the FDA's bulk substances framework [2].

The Difference Between Legal and Accessible

"Legal" means the compound may be prescribed, dispensed, and possessed lawfully under applicable law. "Accessible" is a separate question that depends on insurance coverage, formulary status, and whether a compounder can legally prepare it. In Kentucky, tesamorelin is legal. Whether it is covered by your insurer or available from a compounding pharmacy is a distinct issue addressed in later sections.

Federal Legal Framework for Tesamorelin

FDA Approval History

The FDA approved Egrifta (tesamorelin for injection) on November 10, 2010, under NDA 022505 [1]. A higher-concentration formulation, Egrifta SV (2 mg/vial), received approval in 2019, replacing the original 1 mg product [3]. The approved indication is reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. No other indication has received FDA approval.

Because tesamorelin is an approved drug, it has the same legal standing as any other prescription pharmaceutical. A licensed prescriber in any U.S. State, including Kentucky, may write a prescription for Egrifta. A licensed pharmacy may fill it.

Controlled Substance Scheduling

Tesamorelin does not appear on Schedule I, II, III, IV, or V of the federal Controlled Substances Act [4]. The Drug Enforcement Administration has not scheduled it. Kentucky's controlled substance schedules, maintained under KRS Chapter 218A, mirror federal scheduling for most compounds and add state-specific entries for certain synthetic cannabinoids and opioids. Tesamorelin is absent from both lists [5].

This means no DEA registration is required to prescribe or dispense it, no triplicate prescription form is required in Kentucky, and possession by a patient with a valid prescription carries no criminal penalty under either federal or state law.

FDA's Bulk Compounding List and Tesamorelin

The FDA divides bulk drug substances used in compounding into categories. Category 1 substances are nominated for the "positive list" and may be used by 503A pharmacies while under evaluation. Category 2 substances are nominated but present "significant safety risks, lack of a clinical need, or insufficient evidence of effectiveness" [2].

The FDA placed tesamorelin on the Category 2 list for 503A compounding. Practically, this means traditional compounding pharmacies (503A) should not be preparing tesamorelin for individual patient prescriptions. The FDA's position reflects the existence of an approved product: when a commercially available approved drug exists, the clinical need for a compounded version is harder to justify [2].

503B outsourcing facilities operate under different rules and may compound certain drugs for healthcare facilities without patient-specific prescriptions, but they are also prohibited from compounding drugs that are essentially copies of commercially available products unless there is a documented difference (e.g., alternative concentration or route) with clinical justification [6].

The net effect: compounded tesamorelin in Kentucky is not a straightforward legal option under current FDA guidance.

Kentucky State Law and Tesamorelin

Kentucky Board of Pharmacy

The Kentucky Board of Pharmacy (KBOP) licenses pharmacies and pharmacists operating in the state and enforces both state pharmacy law (KRS Chapter 315) and applicable federal law, including the Drug Quality and Security Act (DQSA) of 2013, which governs compounding pharmacies [7]. KBOP has not issued any state-specific guidance singling out tesamorelin. The federal framework therefore controls.

A licensed Kentucky pharmacy filling a prescription for brand-name Egrifta is acting entirely within state and federal law. A 503A compounding pharmacy in Kentucky that prepares tesamorelin would be operating in tension with the FDA's Category 2 determination and could face enforcement action.

Kentucky Medical Practice Act

Under KRS 311.571, Kentucky-licensed physicians hold broad authority to prescribe any FDA-approved drug for any indication, including off-label uses, provided the decision is consistent with accepted medical practice [8]. The Kentucky Board of Medical Licensure (KBML) has not issued a rule restricting off-label prescribing of tesamorelin.

This means a Kentucky physician may legally prescribe Egrifta to a patient who does not have HIV-associated lipodystrophy, such as a patient with non-HIV visceral obesity or growth hormone deficiency, as long as the clinical rationale is documented. The prescription would be for brand-name Egrifta because the compounding pathway is restricted, and insurance would almost certainly not cover an off-label use.

Nurse Practitioners and Physician Assistants in Kentucky

Kentucky NPs operate under collaborative practice agreements with a supervising physician (KRS 314.011) [9]. Under such agreements, NPs may prescribe Schedule III-V controlled substances and non-controlled prescription drugs, including Egrifta. PAs in Kentucky similarly prescribe under physician supervision per KRS 311.840 [10]. Either provider type may lawfully prescribe tesamorelin.

Clinical Evidence Supporting Tesamorelin Use

Understanding the clinical evidence helps explain why physicians prescribe it and why payers sometimes cover it.

GHRH Analogue Mechanism

Tesamorelin has a half-life of approximately 26 minutes after subcutaneous injection [11]. It stimulates pulsatile GH release rather than flooding the system with exogenous GH, which produces a more physiologic GH and IGF-1 response and avoids the supraphysiologic IGF-1 levels seen with direct GH administration.

Key Efficacy Trials

The key Phase 3 trials submitted to support FDA approval enrolled HIV-positive adults with abdominal fat accumulation confirmed by CT scan. In the combined Phase 3 dataset (N=816), tesamorelin 2 mg daily for 26 weeks reduced visceral adipose tissue (VAT) by a mean of 18% versus a 2% increase in the placebo group (P<0.001) [12]. Triglycerides fell by a mean of 50 mg/dL in the tesamorelin group compared with essentially no change on placebo [12].

A 52-week extension study showed that patients who continued tesamorelin maintained VAT reductions, while those switched to placebo experienced VAT rebound within 26 weeks [13]. The recurrence on discontinuation is clinically relevant: it means ongoing therapy is typically required to maintain benefit.

Safety Profile

Common adverse effects reported in trials include injection-site reactions (25%), fluid retention (edema, 10%), arthralgia (8%), and glucose elevations (fasting glucose increase of approximately 4 mg/dL versus placebo) [12]. The FDA label includes a warning for fluid retention and a contraindication in patients with active malignancy, because GH secretagogues theoretically stimulate IGF-1, which promotes cell growth [1]. Patients with diabetes or pre-diabetes require closer glucose monitoring.

How to Get Egrifta (Tesamorelin) Legally in Kentucky

The access pathway has four steps. Each is necessary. Skipping any one of them places the patient or provider outside the legal framework.

Step 1: Establish a Valid Prescriber-Patient Relationship

Kentucky law requires a prescriber-patient relationship before any prescription drug is written. For controlled substances, a Kentucky-specific form is required, but tesamorelin is not controlled. For non-controlled drugs, the relationship may be established through an in-person visit or, under current Kentucky telehealth rules, through a synchronous audio-video encounter that meets KBML standards [14].

Since the COVID-19 public health emergency ended, Kentucky has maintained rules that allow telemedicine prescribing for non-controlled substances when the prescriber is licensed in Kentucky and a proper evaluation occurs. A prescriber practicing only in another state would need a Kentucky license or a qualifying reciprocal arrangement to legally prescribe to a Kentucky patient.

Step 2: Document the Clinical Indication

For on-label prescribing, the chart must document HIV-positive status, antiretroviral therapy, and excess visceral abdominal fat confirmed by physical examination or imaging. Payers (including Medicaid) typically require prior authorization with supporting documentation [3].

For off-label prescribing, the physician should document the clinical rationale, note that no FDA-approved alternative exists for the specific off-label indication, and obtain informed consent discussing the off-label nature of the use. This is standard practice under KRS 311.571 and KBML guidance [8].

Step 3: Send the Prescription to a Licensed Pharmacy

Egrifta SV (2 mg/vial) is the currently marketed formulation. It requires refrigeration and is dispensed as a lyophilized powder reconstituted with sterile water before injection. The prescription should specify:

• Drug name: Egrifta SV (tesamorelin for injection)
• Dose: 2 mg subcutaneous once daily
• Quantity: typically a 30-day supply
• Reconstitution instructions included with packaging

Any Kentucky-licensed retail or specialty pharmacy with access to a cold-chain distribution network can fill the prescription. Specialty pharmacies handling injectable biologics are the most common dispensing channel given the cold-storage requirement.

Step 4: Confirm Prior Authorization if Using Insurance

For HIV-positive patients, many commercial plans and Kentucky Medicaid may cover Egrifta with prior authorization. The American Association of Clinical Endocrinology (AACE) supports GH secretagogue use in HIV-associated lipodystrophy [15]. Prior authorization forms typically require the prescribing physician to confirm the HIV diagnosis, current ART regimen, and VAT excess.

Patients without insurance or with off-label use typically pay out of pocket. Theratechnologies offers a patient assistance program; patients can inquire through the manufacturer's website.

Telehealth Access to Tesamorelin in Kentucky

Kentucky amended its telehealth statutes following the end of the federal PHE. Under KRS 211.332 and the KBML's 2023 guidance, a physician licensed in Kentucky may prescribe non-controlled prescription drugs via telehealth after a synchronous audio-video evaluation that includes a history and a clinically appropriate physical assessment [14]. Blood tests and imaging may be ordered remotely and reviewed before prescribing.

Telehealth platforms, including HealthRX, that employ Kentucky-licensed physicians may initiate an Egrifta prescription through this pathway. The prescription must still be filled at a Kentucky-licensed pharmacy or a licensed out-of-state pharmacy that has registered to ship into Kentucky under applicable law.

Prescribers should verify that their malpractice coverage extends to telehealth encounters and that their state license is active and unrestricted. Patients should confirm the telehealth platform employs a provider actually licensed in Kentucky, not merely licensed in another state.

Why Compounded Tesamorelin Is Not a Reliable Option in Kentucky

Several online "peptide clinics" advertise compounded tesamorelin. Patients considering this should understand the regulatory field.

503A Pharmacy Restrictions

The FDA's placement of tesamorelin on the Category 2 bulk substances list means a 503A pharmacy that compounds it is not in compliance with federal law as interpreted by the FDA [2]. This does not automatically create criminal liability for patients who unknowingly receive it, but it does mean:

• The pharmacy may be subject to FDA warning letters or enforcement action.
• Quality controls (potency, sterility testing) are not guaranteed.
• The prescribing physician takes on significant liability for directing a patient to a non-compliant dispenser.

A 2021 FDA warning letter to a 503A pharmacy specifically cited unapproved bulk peptides as a basis for enforcement action, demonstrating that the FDA does pursue these cases [16].

Research Chemical Vendors

Some websites sell tesamorelin labeled "for research use only, not for human use." Purchasing this product for self-administration in Kentucky is not a legally protected activity. It does not come with verified potency or sterility. The "research only" label is a legal disclaimer that does not protect the buyer from regulatory action if the product is found to be an adulterated or misbranded drug under 21 U.S.C. 331 [17].

The FDA's position, stated in multiple guidance documents, is that selling a compound with labeling that implies it is not intended for human use does not change its regulatory status as a drug if it is marketed with implied human-use intent [17].

Tesamorelin vs. Other GH Secretagogues: A Quick Legal Comparison

Understanding how tesamorelin compares to other peptides in this class helps clarify why its legal pathway is more straightforward.

Sermorelin, another GHRH analogue, lost FDA approval in 2008 when Serono withdrew it from the market. The FDA allowed 503A compounding of sermorelin because no commercially available approved product existed, a different standard than tesamorelin's situation [18]. Ipamorelin is a ghrelin mimetic with no FDA approval and no recognized compounding pathway. CJC-1295 is similarly unapproved.

Tesamorelin's FDA-approved status means it has the clearest legal pathway of any GHRH-related peptide currently in use, provided the patient obtains it through the brand-name product with a valid prescription [1].

Cost and Insurance Considerations in Kentucky

Egrifta SV carries a list price above $4,000 per month. For HIV-positive patients with documented lipodystrophy, coverage is possible through:

• Kentucky Medicaid (managed care organizations operating under MCO contracts with CHFS) with prior authorization
• Commercial insurance under the patient's pharmacy benefit, again requiring prior authorization
• The Theratechnologies patient assistance program for uninsured or underinsured patients

AACE's 2023 clinical practice guidelines on HIV-related metabolic complications note that "tesamorelin 2 mg/day subcutaneously is the only pharmacotherapy approved specifically for HIV-associated lipodystrophy and is recommended as first-line treatment when pharmacotherapy is warranted" [15]. That guideline citation strengthens prior authorization appeals.

For off-label prescribing scenarios, coverage is unlikely and patients should plan for full out-of-pocket cost.

Summary of the Legal Pathway in Kentucky

Tesamorelin is a federally approved, non-scheduled prescription drug. Kentucky law imposes no additional restrictions beyond standard prescription drug rules. The legal access pathway is: see a licensed Kentucky provider, receive a written prescription for Egrifta SV 2 mg, and fill it at a licensed pharmacy. Compounding pharmacies may not reliably provide a legal product under current FDA guidance. Off-label prescribing is permitted under KRS 311.571, though insurance will not typically cover it outside the approved HIV lipodystrophy indication.

Patients who receive tesamorelin from an unregulated online vendor, a non-compliant compounder, or without a valid prescription are outside the legal framework described here.